Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Mixed-Reality headset trains eyes to work together in adults with lazy eye

NCT ID NCT07819552

Symptom relief Sponsor: Polytechnic Institute of Porto Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 15, 2026 · Last updated Sep 18, 2026 · Updated 2 times

Summary

Researchers are testing whether a home-based augmented reality therapy can improve vision in adults with anisometropic amblyopia, a type of lazy eye. Participants use a mixed-reality headset during daily activities, with the image to the stronger eye dimmed to encourage the weaker eye to work harder. The trial compares this active therapy with a placebo training to see if it improves visual acuity and binocular vision, and whether any gains last six months after treatment ends.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
augmented reality-based binocular therapy delivered through a mixed-reality headset
What this could lead to
If it works, this could offer adults with lazy eye a home-based training option that improves vision without surgery or eye patches.
What could go wrong
The trial is small and early, and vision improvements may not last or may not generalise beyond the specific type of lazy eye studied. Some participants may find the training schedule demanding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2026

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 40 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 40 years. * Diagnosis of anisometropic amblyopia, defined as unilateral amblyopia with an interocular difference of at least 2 lines in best-corrected visual acuity (BCVA), with BCVA worse than 20/32 in the more affected eye. Exclusion Criteria: * Amblyopia other than anisometropic amblyopia. * Bilateral amblyopia. * Ophthalmologic or neuro-ophthalmologic disease other than amblyopia. * Neurological disease, chronic pharmacological therapy, or implanted medical devices. * Any ocular surgery or ocular treatment within the previous year. * Significant media opacities that may prevent fundus examination. * Inability to provide informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Amblyopia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

amblyopia ametropic amblyopia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Amblyopia Anisometropic amblyopia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), University of Coimbra

    RECRUITING

    Coimbra, Coimbra District, 3000-548, Portugal

  • RISE-Health, Center for Translational Health and Medical Biotechnology Research (TBIO), School of Health, Polytechnic of Porto

    RECRUITING

    Porto, Porto District, 4200-072, Portugal

More trials for these conditions

Other studies related to the condition(s) this trial covers.